SEQUENCE LISTING

<110> THERAPTOSIS S.A.

<120> "Peptides having, for example, an antiangiogenic activity and application thereof in therapeutics"

<130> CP/61114-PCT

<150> FR 02 11 270

<151> 2003-09-25

<160> 30

<170> PatentIn version 3.1

<210> 1

<211> 26

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> either a G or a GG, the amino-terminal end of which is free, alkylated, acylated, in particular acetylated, or contains a labeling group such as the biotinyl group.

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> either a C, in which case X in the 2-position = X in the 9 position, the two Cs then being connected by a disulfide bridge, or X in the 2-position is capable of forming a lactam bridge with X in the 4-position, one of X in the 2-position or X in the 9-position being an amino acid bearing an acid group, such as A or D, the other bearing an amino function, such as Q or N.

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> either a C, in which case X in the 2-position = X in the 9 position, the two Cs then being connected by a disulfide bridge, or X in the 2-position is capable of forming a lactam bridge with X in the 9-position, one of X in the 2-position of X in the 9-position being an amino acid bearing an acid group, such as A or D, the other bearing an amino function, such as Q or N.

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> either a C, in which case X in the 2-position = X in the 9 position, the two Cs then being connected by a disulfide bridge, or X in the 2-position is capable of forming a lactam bridge with X in the 4-position, one of X in the 2-position or X in the 9-position being an amino acid bearing an acid group, such as A or D, the other bearing an amino function, such as Q or N.

<220>

<221> MISC_FEATURE

<222> (17)..(17)

<223> either an R motif or a K motif

<220>

<221> MISC_FEATURE

<222> (21)..(21)

<223> either an R motif or a K motif

<220>

<221> MISC_FEATURE

<222> (24)..(24)

<223> either an R motif or a K motif

<220>

<221> MISC_FEATURE

<222> (26)..(26)

<223> is an aliphatic amino acid, the C-terminal end of which is amidated.

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> either an M motif or a norleucine motif

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> either a motif, or a succession of two di-, tri- or tetrapeptide motifs composed of G or of a combination of G and of S, such as GG, GGG, GGGG, GGS, GGGS or GGSGGS, or else X in the 5-position is a C motif, the side chain of which serves as a point for covalent bonding with a 3-nitro-2-pryidinesulfenyl group ...

<400> 1

Xaa Xaa Arg Gly Asp Xaa Phe Gly Xaa Xaa Leu Leu Phe Ile His Phe
1 5 10 15

Xaa Ile Gly Ser Xaa His Ser Xaa Ile Xaa
20 25

<210> 2

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<400> 2

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 3

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<400> 3

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Arg Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 4

<211> 27

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<400> 4

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 5

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<400> 5

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Ser Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 6

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<400> 6

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 7

<211> 29

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<220>

<221> MISC_FEATURE

<222> (19)..(19)

<223> NR representing an N-alkylarginine motif

<400> 7

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Asn Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 8

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<400> 8

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 9

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<400> 9

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 10

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(9)

<223>

<400> 10

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 11

<211> 8

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> the RGD motif via a lactam bridge between the amino acids X (X)-C-O-NH-(X'), X and X' being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> the RGD motif via a lactam bridge between the amino acids X (X)-C-O-NH-(X'), X and X' being amino acids such that one bears an acid group and the other bears an amine

<400> 11

Xaa Arg Gly Asp Met Phe Gly Xaa
1 5

<210> 12

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 12

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly
20 25

<210> 13

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 13

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

Phe Phe Arg Ile Gly Cys Arg Phe Ser Arg Ile Gly
20 25

<210> 14

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 14

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 15

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 15

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Arg Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 16

<211> 27

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 16

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 17

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 17

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Ser Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 18

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 18

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 19

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (19)..(19)

<223> NR representing an N-alkylarginine motif

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 19

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 20

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 20

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 21

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 21

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 22

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 22

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 23

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> X in the 3-position and X in the 10-position being amino acids such that one bears an acid group and the other bears an amine

<400> 23

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 24

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<220>
<221> MOD_RES
<222> (28)..(28)
<223> AMIDATION

<400> 24
Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 25
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MOD_RES
<222> (28)..(28)
<223> AMIDATION

<220>
<221> Disulfide
<222> (3)..(10)
<223>

<400> 25
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Ala Ile Gly Ser Arg His Ser Ala Ile Gly
20 25

<210> 26
<211> 27

<212> PRT

<213> Human HIV

<220>

<221> MOD_RES

<222> (27)..(27)

<223> AMIDATION

<400> 26

Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Leu Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 27

<211> 16

<212> PRT

<213> Human HIV

<220>

<221> MOD_RES

<222> (16)..(16)

<223>

<400> 27

Leu Leu Phe Ile His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
1 5 10 15

<210> 28

<211> 12

<212> PRT

<213> Human HIV

<220>

<221> MOD_RES

<222> (12)..(12)

<223>

<400> 28

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly
1 5 10

<210> 29

<211> 12

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<220>

<221> MOD_RES

<222> (12)..(12)

<223>

<400> 29

Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly
1 5 10

<210> 30

<211> 12

<212> PRT

<213> Human HIV

<220>

<221> Disulfide

<222> (3)..(10)

<223>

<220>

<221> MOD_RES

<222> (12)..(12)

<223>

<400> 30

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly
1 5 10